

# Celgene s.r.o.

## Methodological Statement

*summarizing the methodologies used in preparing the disclosure of transfers of value to healthcare professionals and healthcare organisations pursuant to Section 3.05 of the AIFP Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations, the “Code”*

### **Introduction**

Celgene s.r.o. (“**Celgene**”) is responsible for the sales support and marketing of medicinal products in the Czech Republic.

Celgene also collaborates both directly and through its parent company, Celgene Corporation<sup>1</sup>, in pre-clinical research and clinical trials in the Czech Republic.

In the course of these activities, Celgene engages with healthcare professionals whose registered practice addresses are in the Czech Republic and with healthcare organisations based in the Czech Republic.

The disclosures that Celgene has submitted to the AIFP represent the transfers of value that Celgene has made to such healthcare professionals and healthcare organisations during the course of 2015 insofar as those transfers of value fall within Celgene’s disclosure obligations as defined in the Code.

### **Methodology**

The data upon which Celgene’s disclosures are based has been collected and compiled by Celgene Corporation’s Spend Transparency Office based in Summit, New Jersey. The Spend Transparency Office is responsible for the disclosure of transfers of value to healthcare professionals and healthcare organisations made by any Celgene Corporation affiliate worldwide in accordance with relevant local laws and codes of practice.

In order to prepare for compliance with the Disclosure Code, the Spend Transparency Office first identified all of the possible sources of information within the Celgene Corporation finance system and held by third party vendors that could identify any and all payments made by Celgene. Using information supplied by IMS Health, verified and supplemented by various commercial operations

---

<sup>1</sup> For the purposes of this document alone, the term “Celgene Corporation” refers to Celgene Corporation and all of its affiliates, sub-contractors and agents worldwide.

resources within Celgene and Celgene Corporation, publically available information and information from third party vendors, the Spend Transparency Office narrowed down the list of payees to those that fell within the definitions of healthcare professional and healthcare organisation, as set out in the Code. Celgene used the IMS OneKey Code, as well as identification number of healthcare professional assigned by Czech Medical Chamber or Czech Chamber of Pharmacists and identification number of healthcare organisation as unique identifiers of any given healthcare professional or healthcare organisation.

On the basis of these data Celgene has used its best endeavours to disclose to AIFP for publication on its central platform all direct and indirect transfers of value made between 1 January 2015 and 31 December 2015 that fall within its disclosure obligations as set out in the Code, applying the relevant definitions contained therein. Celgene undertakes to submit promptly to the AIFP any corrections or additions that may be required as a result of knowledge acquired after the date the disclosures are submitted.

### ***Third parties***

Celgene has included in its contractual templates, on the basis of which it contracts with all third parties, a binding clause requiring the third party to notify to Celgene all transfers of value made to healthcare professionals and healthcare organisations. Celgene has used its best endeavours to include all such transfers of value so notified within the scope of its disclosures to the AIFP.

### ***Distributors***

Celgene does not market its products through distributors in the Czech Republic.

### ***Cross border transactions***

Celgene Spend Transparency Office has worked with all of Celgene's functions and affiliates worldwide to capture data relating to transfers of value made by them to healthcare professionals with their practice address in the Czech Republic and healthcare organisations based in the Czech Republic. Celgene has used its best endeavours to include all such transfers of value within its disclosures to AIFP.

### ***Consent***

Celgene has used its best endeavours to seek consent from all healthcare professionals to disclosure on an individual basis, naming the recipient and identifying the value of the transfer. To this end, Celgene has incorporated the corresponding consent language in its contractual templates on the basis of which, pursuant to Celgene's relevant policies, all such engagements should proceed.

In the event that a healthcare professional has declined to give their consent to such individual disclosure, the Country Manager of Celgene, or her designee, has considered in each case whether there is an overriding need to pursue the potential engagement with the result that any transfer of value may only be disclosed in aggregate pursuant to the Code. Factors that are relevant to this consideration include whether the healthcare professional has special knowledge and skills that are not available to Celgene from another healthcare professional willing to give consent to individual disclosure.

In circumstances where a healthcare professional declines to give, or subsequently withdraws, consent to one or more transfers of value in the course of the 2015 reporting year, Celgene has disclosed all transfers of value made to that healthcare professional in aggregate.

### ***Disclosure in aggregate***

Where the recipients of transfers of value cannot be disclosed for legal reasons, including where a healthcare professional has declined to give consent to disclosure on an individual basis, Celgene has disclosed those transfers of value on an aggregate basis.

Celgene has also disclosed on an aggregate basis transfers of value falling within the definition of “*Research and Development Transfers of Value*” pursuant to the Code. Celgene will duly keep records of all payments and other provisions of value falling within the definition of “*Research and Development Transfers of Value*” for period of 5 years at minimum.

Transfers of value made by Celgene that do not fall within the categories that must be disclosed individually or in aggregate pursuant to the Code will not be disclosed.

### ***Currency***

Celgene has made its disclosures in Czech Korunas (CZK), using a published monthly average exchange rate with Czech Korunas (CZK) for those payments made in any other currency.

### ***Tax***

Celgene has made its disclosures relating to direct transfers of value exclusive of all applicable taxes. It is possible, however, that some indirect transfers of value made by third party vendors have been reported to us inclusive of taxes.

### ***Date methodology***

Celgene has made its disclosures relating to cash payments by reference to the payment date. In circumstances where transfers of value represent benefits in kind Celgene has made its disclosures by reference to the date of the event.

### ***Multi-year contracts***

Celgene has not identified any multi-year contracts that fall within its disclosure obligations for 2015.

Prepared by

Celgene s.r.o., Czech Republic

Celgene Corporation, Spend Transparency Office, Summit, New Jersey, United States of America

On 30-06-2016